{
  "id": 4090304,
  "title": "Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy",
  "url": "https://urgent.news/2026/08/29/eplontersen-trial-fails-to-meet-primary-endpoint-in-transthyretin",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-29T02:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-eplontersen-trial-primary-endpoint-transthyretin.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary efficacy endpoint, according to results presented at ESC Congress 2026. ATTR-CM, a progressive and fatal disease characterized by misfolded transthyretin (TTR) amyloid deposits in the heart muscle, affects an estimated 300,000 to 500,000 people worldwide. Eplontersen, a once-monthly RNA-targeted silencer, is approved for the treatment of hereditary/variant TTR amyloid polyneuropathy. The trial, a double-blind Phase III study conducted at 130 centers in 20 countries, enrolled 1,432 patients with ATTR-CM who were receiving standard care. While eplontersen suppressed circulating serum TTR, the trial did not demonstrate a significant reduction in the primary endpoint of cardiovascular mortality and recurrent cardiovascular events in the overall population. However, among patients not receiving stabilizer therapy at baseline, eplontersen monotherapy showed a treatment effect that reached nominal statistical significance.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}